Inactive Instrument

Diffusion Pharma

Equities

DFFN

US2537484048

Diffusion Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

March 18, 2022 at 04:21 pm

Diffusion Pharmaceuticals Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 24.1 million compared to USD 14.19 million a year ago. Basic loss per share from continuing operations was USD 12.5 compared to USD 15 a year ago.

Latest news about Diffusion Pharma

Diffusion Pharmaceuticals Inc.(NasdaqCM:DFFN) dropped from NASDAQ Composite Index	23-08-17	CI
CervoMed Completes Merger with EIP Pharma	23-08-16	MT
EIP Pharma, Inc. completed the acquisition of Diffusion Pharmaceuticals Inc. in a reverse merger transaction.	23-08-15	CI
Diffusion Pharmaceuticals Shareholders Approve Merger With EIP Pharma; Shares Rise	23-08-15	MT
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Diffusion Pharmaceuticals Inc. Appoints Jill Davidson as A Director of the Company, Effective July 26, 2023	23-07-31	CI
Diffusion Pharmaceuticals Inc. Announces Resignation of William K. Hornung as CFO	23-05-19	CI
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Top Premarket Gainers	23-04-17	MT
Diffusion Pharmaceuticals, EIP Pharma Agree to Merge to Create New Combined Entity	23-03-30	MT
EIP Pharma, Inc. entered into a definitive merger agreement to acquire Diffusion Pharmaceuticals Inc. for $22.2 million in a reverse merger transaction.	23-03-29	CI
Diffusion Pharmaceuticals Inc. Announces Resignation of Christopher D. Galloway as Chief Medical Officer, Effective March 1, 2023	23-02-16	CI
Diffusion Pharmaceuticals Enters Reaches Deal With LifeSci Special Opportunities Master Fund on Board Nominees	22-12-16	MT
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities	22-12-16	CI
Diffusion Pharmaceuticals Inc Sends a Letter to Shareholders	22-12-05	CI
Diffusion Pharmaceuticals Inc Solicits Proxies from Shareholders	22-12-01	CI
Diffusion Pharmaceuticals Inc Solicits Proxies from Shareholders	22-11-28	CI
Diffusion Pharmaceuticals Inc Send a Letter to Shareholders	22-11-28	CI
LifeSci Special Opportunities Master Fund Ltd Issues an Open Letter to Shareholders of Diffusion Pharmaceuticals Inc	22-11-18	CI
LifeSci Special Nominates Candidates to the Board of Diffusion Pharmaceuticals	22-11-17	CI
LS Capital, Inc., on behalf of a client and unaffiliated investor in Diffusion Pharmaceuticals Inc. cancelled the acquisition of remaining shares of Diffusion Pharmaceuticals Inc..	22-11-16	CI
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Diffusion Pharmaceuticals Inc. Announces Resignation of Eric Francois from the Board of Directors and All Committees and Subcommittees	22-11-14	CI
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives Including Opportunities to Better	22-10-25	CI
North American Morning Briefing : Investors Seek -2-	22-08-17	DJ

Chart Diffusion Pharma

Duration

Period

More charts

Company Profile

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapies that may enhance the body's ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's intractable and difficult-to-treat conditions, including hypoxic solid tumors, such as GBM. TSC is the therapeutic candidate specifically designed to enhance the oxygen diffusion process. By supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points of the circulatory system. Hypoxia is a complicating factor in many other intractable and difficult-to-treat conditions, including cardiovascular diseases, cerebrovascular diseases, respiratory diseases, skin and soft tissue diseases, and neurodegenerative diseases.

Sector

More about the company